North Carolina is currently home to 2618 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
NCT06143514
Recruiting
The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: PROVIDE Virtual Research Coordination Center, Wilmington, North Carolina
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT06131398
Recruiting
The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/26/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Advanced Solid Tumors
Register for Updates
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
NCT06075095
Recruiting
The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of: 1. A screening and placebo run-in period of approximately 2 weeks prior to first dosing 2. Three treatment periods of approximately 4 weeks each (one period... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/26/2025
Locations: Research Site, Raleigh, North Carolina
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
NCT06001827
Recruiting
This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Surgical Specialists of Charlotte, P.A., Charlotte, North Carolina
Conditions: Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure, ESRD, Vascular Access Complication, Renal Failure, Catheter Complications, Catheter Dysfunction, Renal Insufficiency
Register for Updates
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
NCT05964413
Recruiting
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: University of North Carolina at Chapel Hill Department of Dermatology, Chapel Hill, North Carolina
Conditions: Pyoderma Gangrenosum
Register for Updates
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
NCT05859334
Recruiting
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, Recurrent Glioma
Register for Updates
Identifying Challenges to Healthy Aging in Persons With Human Immunodeficiency Virus (HIV) Age 50 and Older
NCT05858034
Recruiting
The primary objective of this study is to identify and characterize frailty and pre-frailty in persons age 50 and older living with human immunodeficiency virus (HIV) followed by the Atrium Health Wake Forest Baptist Infectious Diseases Specialty Clinics (IDSC).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/26/2025
Locations: Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina
Conditions: HIV, Aging
Register for Updates
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
NCT05766839
Recruiting
A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia
Gender:
ALL
Ages:
11 years and below
Trial Updated:
03/26/2025
Locations: Duke University Hospital & Medical Center, Durham, North Carolina
Conditions: Hyperkalemia
Register for Updates
Collaborative Care for Anxiety and Depression in Epilepsy
NCT05559749
Recruiting
This is a randomized effectiveness/implementation trial comparing a 24-week neurology-based collaborative care intervention to usual neurology care among 60 adults with epilepsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Epilepsy, Anxiety, Depression
Register for Updates
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
03/26/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Early Alzheimer's Disease
Register for Updates
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
NCT05411094
Recruiting
This phase I trial tests the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Locally Advanced Pancreatic Carcinoma, Unresectable Pancreatic Carcinoma
Register for Updates
Autologous Muscle Fiber Fragment Injections
NCT05396456
Recruiting
To regenerate functional anal sphincter muscle using muscle fiber fragments that contain muscle precursor cells (MPCs)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Fecal Incontinence
Register for Updates